I appreciate the attention Schrijnders et al. (1) have given to the Counterpoint article on use of sulfonylureas as an add-on to metformin (2). Several sulfonylureas were compared with regard to the risk of hypoglycemia, but gliclazide was neglected, as it is unfortunately not available in the U.S. Gliclazide was also not mentioned in the Point article by Abrahamson (3), possibly for the same reason. Given the favorable data cited by Schrijnders et al. (4), gliclazide would be a welcome replacement for glyburide in the U.S. market as monotherapy or when appropriate as an add-on to metformin. This is especially so if randomized clinical trial data ever confirm the cohort study evidence of gliclazide superiority with regard to mortality and cardiovascular events (4,5).
Article Information
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
